SPYRE THERAPEUTICS, INC. (SYRE) Current Ratio
- Current ratio · latest quarter: Value 18.53×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 18.53× | Current assets / current liabilities. $1.17B ÷ $63.30M ≈ 18.53× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.17B USD | Assets, Current |
| Current obligations | 63.30M USD | Liabilities, Current |
| Cash and equivalents | 162.01M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 983.34M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.17B | $63.30M | $162.01M | $983.34M | (m) | (m) | (m) | (m) | 18.53× |
| 2026-03-31 | $763.95M | $85.16M | $97.19M | $644.28M | (m) | (m) | (m) | (m) | 8.97× |
| 2025-12-31 | $777.78M | $58.69M | $85.72M | $670.81M | (m) | (m) | (m) | (m) | 13.25× |
| 2025-09-30 | $504.60M | $46.27M | $64.90M | $421.30M | (m) | (m) | (m) | (m) | 10.90× |
| 2025-06-30 | $538.83M | $83.06M | $81.66M | $444.92M | (m) | (m) | (m) | (m) | 6.49× |
| 2025-03-31 | $569.77M | $70.68M | $48.49M | $516.33M | (m) | (m) | (m) | (m) | 8.06× |
| 2024-12-31 | $608.47M | $54.06M | $89.42M | $513.66M | (m) | (m) | (m) | (m) | 11.26× |
| 2024-09-30 | $421.08M | $57.54M | $71.58M | $342.65M | (m) | (m) | (m) | (m) | 7.32× |
| 2024-06-30 | $435.74M | $22.12M | $45.14M | $380.85M | (m) | (m) | (m) | (m) | 19.70× |
| 2024-03-31 | $487.27M | $42.82M | $227.55M | $257.09M | (m) | (m) | (m) | (m) | 11.38× |
| 2023-12-31 | $341.53M | $31.98M | $188.89M | $150.38M | (m) | (m) | (m) | (m) | 10.68× |
| 2023-09-30 | $205.95M | $44.87M | $90.59M | $113.01M | (m) | (m) | (m) | (m) | 4.59× |
| 2023-06-30 | $239.89M | $232.23M | $235.36M | $0.00 | (m) | (m) | $2.85M | (m) | 1.03× |
| 2023-03-31 | $44.38M | $12.64M | $35.24M | $3.23M | (m) | (m) | $2.06M | (m) | 3.51× |
| 2022-12-31 | $62.26M | $14.66M | $34.86M | $20.85M | (m) | (m) | (m) | (m) | 4.25× |
| 2022-09-30 | $82.22M | $17.68M | $38.99M | $34.69M | (m) | (m) | $4.18M | (m) | 4.65× |
| 2022-06-30 | $96.65M | $15.86M | $37.47M | $51.08M | (m) | (m) | $1.96M | (m) | 6.09× |
| 2022-03-31 | $72.60M | $16.30M | $14.64M | $52.09M | (m) | (m) | $2.98M | (m) | 4.45× |
| 2021-12-31 | $98.89M | $20.14M | $15.14M | $77.99M | (m) | (m) | $3.32M | (m) | 4.91× |
| 2021-09-30 | $117.51M | $20.43M | $24.66M | $87.76M | (m) | (m) | $1.86M | (m) | 5.75× |
| 2021-06-30 | $134.37M | $20.60M | $34.77M | $93.81M | (m) | (m) | $2.22M | (m) | 6.52× |
| 2021-03-31 | $151.41M | $32.37M | $80.23M | $46.43M | (m) | (m) | $1.88M | (m) | 4.68× |
| 2020-12-31 | $149.79M | $16.44M | $90.09M | $56.18M | (m) | (m) | $2.25M | (m) | 9.11× |
| 2020-09-30 | $144.40M | $14.35M | $54.22M | $85.75M | (m) | (m) | $2.29M | (m) | 10.06× |
| 2020-06-30 | $161.87M | $15.89M | $65.71M | $92.02M | (m) | (m) | $4.15M | (m) | 10.19× |
| 2020-03-31 | $54.27M | $17.14M | $12.59M | $36.40M | (m) | (m) | $3.62M | (m) | 3.17× |
| 2019-12-31 | $74.50M | $18.36M | $19.25M | $52.70M | (m) | (m) | $3.15M | (m) | 4.06× |
| 2019-09-30 | $92.63M | $15.40M | $24.55M | $64.16M | (m) | (m) | $2.43M | (m) | 6.02× |
| 2019-06-30 | $109.94M | $13.02M | $25.43M | $80.11M | (m) | (m) | $2.72M | (m) | 8.44× |
| 2019-03-31 | $126.82M | $11.81M | $85.64M | $38.07M | (m) | (m) | $3.22M | (m) | 10.74× |
| 2018-12-31 | $76.67M | $10.24M | $22.46M | $52.05M | (m) | (m) | $663.00K | (m) | 7.49× |
| 2018-09-30 | $70.38M | $7.51M | $14.53M | $50.20M | (m) | (m) | $1.08M | (m) | 9.37× |
| 2018-06-30 | $78.89M | $6.17M | $20.58M | $51.61M | (m) | (m) | $952.00K | (m) | 12.78× |
| 2018-03-31 | $48.84M | $5.76M | $10.76M | $32.72M | (m) | (m) | $763.00K | (m) | 8.47× |
| 2017-12-31 | $54.99M | $5.63M | $12.82M | $37.48M | (m) | (m) | $389.00K | (m) | 9.77× |
| 2017-09-30 | $59.52M | $4.88M | $13.16M | $42.59M | (m) | (m) | $615.00K | (m) | 12.20× |
| 2017-06-30 | $66.20M | $4.42M | $26.93M | $36.46M | (m) | (m) | $634.00K | (m) | 14.98× |
| 2017-03-31 | $60.30M | $3.96M | $16.80M | $41.07M | (m) | (m) | $267.00K | (m) | 15.24× |
| 2016-12-31 | $66.42M | $3.96M | $47.75M | $15.75M | (m) | (m) | $168.00K | (m) | 16.75× |
| 2016-09-30 | $71.68M | $3.84M | $49.54M | $18.49M | (m) | (m) | $523.00K | (m) | 18.68× |
| 2016-06-30 | $76.91M | $3.36M | $70.63M | $2.95M | (m) | (m) | $348.00K | (m) | 22.88× |
| 2016-03-31 | $35.20M | $3.82M | $24.02M | $4.97M | (m) | (m) | $509.00K | (m) | 9.22× |
| 2015-12-31 | $38.29M | $2.52M | $29.29M | $3.77M | (m) | (m) | $176.00K | (m) | 15.17× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |